issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged share capital (the “Share Purchase”) at the price of INR 36 per share. The Company would
by its indirect subsidiary Indorama Netherlands B.V. (“INBV”) of 83,000,000 newly issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged
provisions regarding the employees’ savings and the employer’s contribution payable to the fund; (7) the provisions regarding the rules and procedures for the computation of benefits entitled to the employees
provisions regarding the employees’ savings and the employer’s contribution payable to the fund; (7) the provisions regarding the rules and procedures for the computation of benefits entitled to the employees
or 22.90% over the same period of last year of which hospital revenues totally raised by 10.16% along with the enlarged customer base of Subsidiary (AMARC) showing 15.67% of revenues’ growth. In
year, the Company has not yet earned income from Excellence Center (New Building) planned to official grand opening in the following year of February 2018) along with the enlarged customer base of the
shareholders, and subscribe Phoenix’s newly issued shares of 180.00 million shares, totaling 314.60 million shares or 55 percent of total enlarged shares of Phoenix. List of shareholders before and after
performance in 2nd quarter and 6-month period, its cost of services amounted to Baht 21.3 million and Baht 45.4 million, a rise of 12.4% and 20.5% whereas its selling & administrative expenses enlarged at
total value of consideration criterion which granted the highest result, referenced from the consolidated audited financial statement of the Company ended March 31, 2019. After the computation of the
Transaction calculated based on the total value of consideration criterion, which gives the highest transaction value, and after computation with the transaction size of the Company’s other acquisition